Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination
Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination

Nick van Wijk\textsuperscript{a}, Laus M. Broersen\textsuperscript{a}, Martijn C. de Wilde\textsuperscript{a}, Robert J.J. Hageman\textsuperscript{a}, Martine Groenendijk\textsuperscript{a}, John W.C. Sijben\textsuperscript{a}, Patrick J.G.H. Kamphuis\textsuperscript{a,b}

\textsuperscript{a}Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, the Netherlands  
\textsuperscript{b}Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

Reprinted with permission from IOS Press  
Original publication is distributed under the terms of the Creative Commons Attribution NonCommercial License
Abstract

Synapse loss and synaptic dysfunction are pathological processes already involved in the early stages of Alzheimer’s disease (AD). Synapses consist principally of neuronal membranes, and the neuronal and synaptic losses observed in AD have been linked to the degeneration and altered composition and structure of these membranes. Consequently, synapse loss and membrane-related pathology provide viable targets for intervention in AD. The specific nutrient combination Fortasyn Connect (FC) is designed to ameliorate synapse loss and synaptic dysfunction in AD by addressing distinct nutritional needs believed to be present in these patients. This nutrient combination comprises uridine, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B₁₂, B₆, C, and E, and selenium, and is present in Souvenaid, a medical food intended for use in early AD. It has been hypothesized that FC counteracts synaptic loss and reduces membrane-related pathology in AD by providing nutritional precursors and cofactors that act together to support neuronal membrane formation and function. Preclinical studies formed the basis of this hypothesis which is being validated in a broad clinical study program investigating the potential of this nutrient combination in AD. Memory dysfunction is one key early manifestation in AD and is associated with synapse loss. The clinical studies to date show that the FC-containing medical food improves memory function and preserves functional brain network organization in mild AD compared with controls, supporting the hypothesis that this intervention counteracts synaptic dysfunction. This review provides a comprehensive overview of basic scientific studies that led to the creation of FC and of its effects in various preclinical models.
Targeting membrane-related pathology and synaptic loss in Alzheimer’s disease

Membrane-related pathology and synapse loss are central to the pathogenesis of Alzheimer’s disease (AD) and therefore represent compelling targets for intervention in this condition. This review discusses how nutrients and their specific combinations affect the synthesis and composition of neuronal membranes, leading to improved membrane-dependent processes of potential relevance for patients with AD, such as synaptic functioning.

Synaptic dysfunction in the pathogenesis of AD

AD is a chronic neurodegenerative disease characterized by a progressive functional decline in memory and other cognitive domains, with the frequent occurrence of non-cognitive behavioral symptoms and impairments in the ability to perform activities of daily living (Caselli et al. 2006, Pereira et al. 2005). While the cause of AD is unknown, it is widely accepted that multiple genetic and environmental risk factors underlie the development of the disease (Pereira et al. 2005). Characteristic hallmarks of AD include extracellular amyloid-β (Aβ) plaques; intracellular neurofibrillary tangles composed of hyperphosphorylated tau; and a continuous loss of neurons (Ballard et al. 2011, Pereira et al. 2005). Additionally, already in the early stages of the disease there is a loss of synapses (Arendt 2009, Selkoe 2002) that has been shown to precede and exceed neuronal loss (Davies et al. 1987, Masliah et al. 1991). Aβ accumulation is considered an upstream event in the cascade that leads to synaptic loss and synaptic dysfunction (Haass and Selkoe 2007, Koffie et al. 2011, Selkoe 2002, Sperling et al. 2011).

AD-related synapse loss progresses during the course of the disease and leads to a progressive impairment of brain performance and worsening of clinical symptoms (Arendt 2009, Selkoe 2002, Terry 2006). While synaptic loss occurs during normal, non-pathological aging in humans (Masliah et al. 1993), it is far more pronounced in AD (X. Liu et al. 1996, Masliah et al. 1993). This indicates that the disease-induced synaptic loss in AD occurs in addition to age-related synaptic loss. Based on this, it may be hypothesized that the need for renewal of synapses is greater in AD patients than in normal healthy age-matched individuals. Symptomatic dementia manifests when cortical synapse number is reduced by approximately 40% or more compared with age-matched cognitively intact adults (Terry et al. 1991). Synaptic loss is a direct structural correlate with cognitive test performance in AD (DeKosky and Scheff 1990, Terry et al. 1991) and is more robustly
correlated with cognitive deficits than the amount of amyloid plaques or neurofibrillary tangles, or the degree of neuronal loss (Terry et al. 1991). Studies that also include subjects with mild cognitive impairment (MCI) and mild AD indicate that synaptic loss is an early structural correlate in AD (Scheff et al. 2007, Scheff et al. 2006, Scheff et al. 2011). These postmortem findings are in line with imaging biomarker studies in living patients. Although it is not possible to quantify synaptic density and synaptic functioning directly in humans, $^{18}$F-fluorodeoxyglucose positron emission tomography (FDG-PET) (Herholz 2012, Mosconi et al. 2008), functional magnetic resonance imaging (fMRI) (Brickman et al. 2009), and electroencephalography (EEG) (Cook and Leuchter 1996, Siegel et al. 2012, Stam 2011) provide useful biomarkers for synaptic dysfunction and network connectivity in AD progression (de Wilde et al. 2011a). Such imaging markers indicate that synaptic dysfunction is a pathological process involved already in the early stages of the disease, even prior to the onset of clinical AD, i.e., in a preclinical stage or in subjects with MCI (Sperling et al. 2011). In fact, these biomarkers help to differentiate between disease stages and are predictive for risk of progression from cognitive normal subjects to MCI and AD (Sperling et al. 2011, Sperling et al. 2013).

Synapses and neurites consist principally of neuronal membranes that are composed of phospholipid bilayers structurally integrated with, for example, cholesterol, sphingolipids, and a variety of proteins, including ion-channels, receptors, and enzymes (van Meer et al. 2008). Proper membrane lipid homeostasis in neurons is essential for preventing the loss of synaptic function (Mielke and Lyketsos 2006). Neuronal and synaptic losses observed in AD have been linked to the degeneration of neuronal membranes and increased breakdown of membrane phospholipids (Gottfries et al. 1996, Nitsch et al. 1992, Pettegrew et al. 2001, Prasad et al. 1998). In addition to the degeneration of neuronal membranes, alterations in membrane composition and structure are observed in patients with AD. Disturbances in phospholipid composition (Gottfries et al. 1996, Grimm et al. 2011a, Nitsch et al. 1992, Pettegrew et al. 2001, Prasad et al. 1998), levels of plasmalogens (Grimm et al. 2011a, Grimm et al. 2011c, Igarashi et al. 2011), levels of polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA; 22:6n-3) (Astarita et al. 2010, Cunnane et al. 2012, Igarashi et al. 2011, Nakada et al. 1990, Prasad et al. 1998, Soderberg et al. 1991), and the composition of lipid rafts (Martin et al. 2010) have been observed in the AD brain. Neuronal membrane alterations have also been identified in patients with MCI (Han 2010).
The neuronal membrane is the principal site of action for numerous neuronal activities (Yehuda et al. 2002). Biochemical and physical alterations that directly influence the composition and structure of membranes can affect a multitude of membrane-dependent processes (Mielke and Lyketsos 2006). These include receptor and ion channel structure and activity, axonal signal transduction, activity of membrane-bound enzymes, optimal exchange of nutrients and other molecules, and mitochondrial efficiency (Haag 2003, Vigh et al. 2005, Yehuda et al. 2002). Thus, membrane degeneration and alteration of membrane structure have a profound impact on neuronal membrane functioning and consequent neuronal functioning.

Taken together, membrane-related pathology and synapse loss play a central role in the pathogenesis of AD, and consequently provide viable interventional targets. Brain structure and function are known to be influenced by nutrients obtained from the diet (Bourre 2006b, Bourre 2006a). In particular, neurons require specific nutrients for the formation and maintenance of neuronal membranes. As described below, increasing the availability of certain nutrients modulates neuronal membrane formation and function. Consequently, dietary supplementation of specific combinations of nutrients potentially reduces membrane-related pathology and synaptic loss in AD patients.

A specific nutrient combination designed to support synapse formation and function in patients with AD

Fortasyn® Connect (FC) is a specific nutrient combination designed to ameliorate synapse loss and synaptic dysfunction in AD by addressing nutritional needs believed to exist in these patients. This specific nutrient combination is present in Souvenaid®, a medical food intended for early AD patients. FC comprises precursors and cofactors needed for the formation and maintenance of neuronal membranes, i.e., uridine (as uridine monophosphate, UMP), the omega-3 PUFAs DHA and eicosapentaenoic acid (EPA; 20:5n-3), choline, phospholipids, folic acid, vitamin B₁₂, vitamin B₆, vitamin C, vitamin E, and selenium. The precursors for membrane synthesis (DHA, EPA, uridine, choline, and phospholipids) act by enhancing the substrate-saturation of the enzymes that catalyze the rate-limiting steps of membrane phospholipid synthesis. B-vitamins, vitamin C, vitamin E, selenium, and phospholipids act as cofactors by increasing the availability of membrane precursors or by directly affecting the neuronal membrane or membrane synthesis. A schematic summary of the hypothetical effects of FC on neuronal membranes and synapse formation is presented in Fig. 1. The basic scientific studies presented in this review
provide the rationale for this hypothesis and formed the basis for the creation of this specific nutrient combination. Most of these preclinical studies were conducted under supervision of Dr. R.J. Wurtman (Massachusetts Institute of Technology, Cambridge, MA, USA) supported by the National Institutes of Health and the Center for Brain Sciences and Metabolism Charitable Trust. Additional preclinical studies were conducted in collaboration with Dr. A.J. Kiliaan (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands); Dr. P.G.M. Luiten, (University of Groningen, Groningen, The Netherlands), and partners within the LipiDiet (EU FP5, QLK-2002-172) and LipiDiDiet (EU FP7, grant N° 211696) projects led by Dr. T. Hartmann (Saarland University, Homburg, Germany).

The aim of this report is to provide a comprehensive overview of basic scientific studies that led to the creation of FC and of its effects in various in vitro and in vivo models. These studies demonstrate that the nutrients in this specific combination act in concert to modulate neuronal membrane formation and function, and consequently affect synapse formation, neurotransmission, Aβ-related pathology, and cognitive performance. The potential clinical relevance of these effects is being examined in a broad clinical study program in AD patients.
The formation of new synapses requires the synthesis of new neuronal membranes. Intake of the specific nutrient combination Fortasyn Connect increases the availability of circulating membrane precursors and cofactors. Uridine, DHA, EPA, and choline are precursors for phospholipids, which are the main constituents of neuronal membranes. B-vitamins, vitamin C, vitamin E, selenium, and dietary phospholipids act as cofactors by increasing the availability of membrane precursors or by directly affecting the neuronal membrane or membrane synthesis. Combined administration of these nutritional precursors and cofactors is needed to stimulate membrane formation and function (green square). These changes have been shown to be accompanied by increases in neurite outgrowth, levels of specific pre- and post-synaptic proteins, and the number of dendritic spines (purple squares), all prerequisites for new synapse formation.
Effects of nutritional compounds on neuronal membrane formation and function

The formation of new neuronal membranes and the maintenance of membrane composition and structure are highly dynamic processes that occur continuously throughout life (Mielke and Lyketsos 2006). These processes rely upon a sustained supply of neuronal membrane precursors and cofactors, largely provided by the diet. Data summarized below indicate that these nutritional compounds can increase neuronal membrane formation and improve membrane functioning.

Precursor control of membrane formation

The phospholipid bilayer of neuronal membranes is composed of several classes of phospholipids; most common in the mammalian brain are phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), phosphatidylserine (PS), and phosphatidylinositol (PI) (Sastry 1985). Phospholipids themselves are highly heterogeneous, with each class representing a subset of compounds with differing fatty acid compositions.

PC and PE, the most abundant phospholipids in the brain, are synthesized by the cytidine diphosphate (CDP)-choline pathway and the CDP-ethanolamine pathway, respectively. Together these pathways are also known as the Kennedy pathway. A plain overview of the Kennedy pathway is depicted in Fig. 2, right panel (Kennedy and Weiss 1956). SM is usually formed from the combination of ceramide and the phosphocholine unit of PC. PS is made via a base-exchange reaction, in which serine is exchanged for the choline or ethanolamine moiety in PC or PE, respectively. The de novo pathway of PI synthesis starts with the formation of CDP-diacylglycerol (DAG) from DAG 3-phosphate and cytidine triphosphate (CTP). The activated DAG unit then reacts with inositol to form PI (Vance and Vance 2004).
The precursors and cofactors in Fortasyn Connect putatively act on several physiological and biochemical processes as depicted in the three panels. Increasing the formation of synaptic membranes requires a combined increased supply of nutritional membrane precursors and cofactors. Availability of membrane precursors (in red) is affected by their nutritional intake as well as by the intake of cofactors (in green) that increase precursor availability. Dietary phospholipids can increase the availability of the precursors DHA and EPA by increasing their absorption from the gut into the enterocytes and the lymph (left panel). Dietary folate, vitamin B₁₂, and vitamin B₆ intake influences plasma concentration of the precursors DHA and choline as their availability affects methylation capacity and plasma homocysteine levels, which in turn influences the PEMT pathway (middle panel). This especially is relevant in AD, which is associated with high plasma homocysteine levels and B-vitamin deficiencies. Vitamin C, E, and selenium can serve as antioxidants to protect the membrane precursors DHA and EPA (right panel). The precursors for phospholipid synthesis (DHA, EPA, uridine, and choline), required for membrane formation, act by enhancing the substrate-saturation of the enzymes that catalyze the rate-limiting steps in the Kennedy pathway (right panel).

Dietary phospholipids can also act as a direct source of precursors, whereas selenium may stimulate membrane synthesis by increasing the activity of a key enzyme in the Kennedy pathway (right panel). AO, antioxidants; CDP-choline, cytidine diphosphate choline; CTP, cytidine triphosphate; DAG, diacylglycerol; B₆. vitamin B₆; B₁₂. vitamin B₁₂; DHA. docosahexaenoic acid; EPA. eicosapentaenoic acid; FO, folate; HCY, homocysteine; Met, methionine; PEMT, phosphatidylethanolamine-N-methyltransferase; PL, dietary phospholipids; SEL, selenium.
The synthesis of all major membrane phospholipids is dependent on circulating nutritional precursors. For example, the synthesis of PC may utilize choline, a pyrimidine (e.g., uridine), and PUFAs (e.g., DHA). These precursors act by enhancing the substrate-saturation of the enzymes that catalyze the rate-limiting steps in phospholipid syntheses. All three precursors are required to augment the synthesis of PC in neuronal membranes. Because they must be obtained by the brain almost entirely from the circulation, blood levels of these precursors can markedly affect the overall rate of phospholipid synthesis (Wurtman et al. 2009).

Other nutrients act as cofactors in the synthesis of phospholipids, either by increasing the availability of phospholipid precursors (described in more detail below) or by directly affecting the Kennedy pathway. Specifically, selenium may further stimulate PC synthesis by increasing the activity of a key enzyme in the Kennedy pathway, CDP-choline:DAG cholinephosphotransferase (S.Y. Liu et al. 1993).

In a series of preclinical studies, Wurtman and coworkers demonstrated that membrane phospholipid synthesis is synergistically increased by co-administration of uridine, DHA or EPA, and choline, the rate-limiting substrates of the Kennedy pathway. Increasing the availability of these phospholipid precursors increases the levels of key intermediates in the Kennedy pathway. Uridine has been shown to significantly elevate levels of the intermediates uridine triphosphate (UTP), CTP (Pooler et al. 2005, Richardson et al. 2003, Wurtman et al. 2000), and CDP-choline in pheochromocytoma cells (PC-12) (Richardson et al. 2003), a frequently used cell model of neuronal differentiation. Incubation of rat striatal brain slices with uridine increased utilization of choline to form CDP-choline (Ulus et al. 2006). Oral choline administration increased brain phosphocholine levels in rats (Millington and Wurtman 1982), whereas administration of UMP (a source of uridine) increased brain UTP, CTP, and CDP-choline levels in gerbils (Cansev et al. 2005). A recent study in healthy humans indicated that short-term oral uridine administration increased brain levels of the intermediates phosphocholine and phosphoethanolamine (Agarwal et al. 2010).

Several in vitro and in vivo studies have shown that administration of the precursors that increase the levels of Kennedy pathway intermediates also raises brain phospholipid levels. In PC-12 cells, addition of DHA significantly stimulated the incorporation of \(^{14}\)C-choline into total cellular phospholipids (Richardson and Wurtman 2007). Uridine
supplementation to rat striatal brain slices stimulated phospholipid synthesis (Ulus et al. 2006). Supplementation of the omega-3-PUFA DHA (300 mg/kg by gavage) and/or uridine (as UMP, 0.5 g/100 g diet) to gerbils and rats consuming standard choline-containing diets (0.1 g/100 g diet) significantly increased levels of brain phospholipids, PC, PE, SM, PI, and PS, with combined administration inducing the largest effects (Cansev et al. 2009, Cansev et al. 2008a, Cansev and Wurtman 2007, Holguin et al. 2008a, Holguin et al. 2008b, Sakamoto et al. 2007, Wurtman et al. 2006). For example, gerbils that received daily supplementation of UMP or DHA for 4 weeks showed a rise in brain PC of 13–22% compared with control levels. Combined supplementation of UMP and DHA increased PC levels up to 45% of control levels. Similar results were obtained for the other brain phospholipids, in which combined supplementation increased phospholipid levels by 39–74% (Wurtman et al. 2006). These effects were observed irrespective of phospholipid levels being expressed per mg protein or per cell (DNA), indicating that each brain cell contained more membrane phospholipids. Similar to DHA, the omega-3 PUFA EPA induced an increase in brain phospholipid levels in gerbils (Cansev and Wurtman 2007). The effect of EPA was amplified when supplemented in combination with UMP, as was also observed with DHA. EPA possibly acts as a precursor for brain DHA (Hashimoto et al. 2009, Moore et al. 1991). EPA is found only in trace amounts in brain phospholipids (Wurtman et al. 2009); however, after transport to the brain EPA can be converted to DHA through elongation, desaturation, and oxidation steps. Thus, increased dietary intake of EPA could increase brain phospholipid synthesis via metabolism to DHA (Cansev and Wurtman 2007). Unlike DHA and EPA, the omega-6 PUFA arachidonic acid administered orally to gerbils did not promote membrane synthesis (Cansev and Wurtman 2007, Sakamoto et al. 2007). The mechanisms that underlie the differential effects of DHA (and EPA) and arachidonic acid on phospholipid synthesis are not elucidated, but possibly involve differences in substrate specificity of enzymes that utilize omega-3 PUFAs and omega-6 PUFAs prior to and after their incorporation into phospholipids (Cansev and Wurtman 2007).

Other groups have also demonstrated the effects of nutritional precursors or combinations thereof on phospholipid synthesis. The membrane phospholipid content of PC-12 cells was shown to be increased by supplementing a combination of choline plus cytidine (which is a pyrimidine, like uridine) (C.S. Wang and Lee 2000). Increased membrane PS levels were found in neuroblastoma cells supplemented with DHA (Akbar et al. 2005). Shahdat et al. (2004) demonstrated that DHA administered orally significantly increased rat brain phospholipid content. Dietary enrichment with a specific combination
of membrane precursors and cofactors (DHA, EPA, uridine, choline, folate, vitamin B\textsubscript{12}, vitamin B\textsubscript{6}, phospholipids, vitamin C, vitamin E, and selenium, i.e., FC) also increased neuronal membrane PC levels in the intracerebroventricular (ICV) Aβ-infused rat model of AD (de Wilde et al. 2011b).

The above-mentioned studies demonstrated that supplementation with uridine, DHA or EPA, and choline stimulates formation of neuronal membranes. Since each precursor can become rate-limiting in elevating phospholipid synthesis, combined supplementation of these precursors induces a more pronounced effect on neuronal membrane synthesis than single nutrient supplementation.

**Increasing the availability of membrane precursors**

The availability of membrane precursors in the blood and the brain is largely dependent on their nutritional intake (Wurtman et al. 2009). For example, supplementing humans with DHA (Arterburn et al. 2006), choline (Wurtman et al. 1977), or the combination of folic acid, vitamin B\textsubscript{12}, and B\textsubscript{6} (Smith et al. 2010) result in increased levels in the circulation. Few data are available on the effects of oral intake of UMP on plasma levels of uridine in humans. In an experiment described by Cansev et al. (2006), plasma concentration of uridine increased after acute oral intake of UMP. Recently, plasma uridine concentration was measured in healthy human subjects after oral intake of one serving of a medical food containing 625 mg UMP/125 mL. The effect of this medical food was compared with an equimolar UMP solution in water and with a control product that lacked UMP. Mean baseline plasma uridine concentration of all healthy subjects was 6.4 µmol/L. Plasma uridine concentrations were significantly and equally increased following oral intake of the UMP-containing medical food or the UMP solution. One hour after oral intake plasma uridine concentrations peaked at 14.6 µmol/L (medical food) and 14.2 µmol/L (UMP solution), after which uridine concentrations gradually declined toward baseline concentrations in 4 hours. These data indicate that 625 mg UMP either in the medical food or in a water solution is readily absorbed and increases plasma uridine levels up to 240% of basal levels, and that the effects of UMP on postprandial plasma uridine levels is unaffected by the solution matrix (Fig. 3; unpublished data).
The effects of acute oral intake of a UMP-containing medical food on plasma uridine concentration in humans. Healthy subjects received either one serving of the medical food (625 mg uridine monophosphate (UMP)/125 mL), an equimolar UMP solution in water (625 mg UMP/125 mL), or a control product (125 mL) that was isocaloric and similar in flavor and appearance as the medical food but lacked UMP, DHA, EPA, choline, phospholipids, folic acid, vitamin B₁₂, vitamin B₆, vitamin C, vitamin E, and selenium. Baseline samples were taken 5 minutes prior to oral intake. Values are means, with their standard errors represented by vertical bars (n=5 per experimental group). Plasma uridine levels increased after oral intake of either the UMP-containing medical food or the UMP solution but not after oral intake of the control product. Repeated measures analysis of variance (ANOVA) with Bonferroni post-test revealed a significantly increased postprandial uridine curve following intake of either the medical food (p=0.002) or the UMP solution (p=0.002) compared with control. The medical food or the UMP solution did not induce significantly different postprandial curves, i.e., the postprandial uridine curve was unaffected by the solution matrix (p=1.00). The UMP-containing medical food used in this experiment was Souvenaid.

Uridine, choline, and DHA are all known to readily enter the brain. Their transport into the brain involves simple diffusion or passive or active transport by specific membrane transport proteins located at the blood–brain barrier or the choroid plexus (Wurtman et al. 2009). Not surprisingly, experimental data show that plasma levels of membrane precursors influence their levels in the brain. Administration of DHA (Brossard et al. 1996, Connor et al. 1990, Rapoport et al. 2001), choline (Cohen and Wurtman 1976, Klein et al. 1990), and uridine (as UMP) (Cansev et al. 2005) have been shown to directly increase
their levels in the brain. Conversely, lower circulating nutrient levels could limit their utilization by the brain, resulting in reduced neuronal membrane synthesis.

The availability of membrane precursors is not only affected by their nutritional intake, but also by the intake of cofactors that influence precursor uptake, synthesis, degradation, or distribution in the body. The different physiological and biochemical processes involved and the putative role of the precursors and cofactors contained within FC are summarized in Fig. 2.

Folate, vitamin B$_{12}$, and vitamin B$_6$ are essential nutritional components in one-carbon metabolism and are required for methylation capacity. The availability of these vitamins may therefore modify the methylation of PE to PC by phosphatidylethanolamine-\(N\)-methyltransferase (PEMT) in the liver. This has important implications for the metabolism of choline and DHA. By increasing PC synthesis, B-vitamin supplementation could not only increase endogenous choline synthesis, but also reduce choline utilization by the betaine–homocysteine methyltransferase (BHMT) pathway (Holm et al. 2004, Jacob et al. 1999, Park and Garrow 1999, Yan et al. 2011). PC synthesis by PEMT can also influence the transport of PUFAs, like DHA, from the liver to the plasma and other tissues (Pynn et al. 2011, Selley 2007, Watkins et al. 2003). Recent experiments in rats have confirmed these hypotheses by demonstrating that combined dietary folic acid, vitamin B$_{12}$, and vitamin B$_6$ supplementation increases concentrations of plasma choline (van Wijk et al. 2012a) and DHA (van Wijk et al. 2012b). In this way, intake of supplemental B-vitamins may increase the availability of choline and DHA (Fig. 2, middle panel). Conversely, B-vitamin deficiencies and concurrent high plasma homocysteine levels, as commonly observed in AD (van Dam and van Gool 2009), may impair the transport of DHA from the liver, decrease the synthesis of choline, and increase the utilization of choline. It can therefore be expected that combined intake of B-vitamins, DHA, and choline by individuals with a low B-vitamin status and/or high plasma homocysteine level, would be more effective in increasing DHA and choline availability than intake of DHA and choline alone.

Dietary phospholipids can increase precursor availability by two distinct mechanisms. First, phospholipids act as a direct source of precursors. Dietary phospholipids are digested into fatty acids, lysophospholipids, phosphatidic acid, glycerol, monoglycerides, and other compounds, including choline and ethanolamine. These digestion products are subsequently absorbed and either further metabolized or directly used as precursors for
neuronal membrane synthesis (Fig. 2, right panel). For example, the intake of phospholipids has been shown to increase levels of choline in human plasma (Wurtman et al. 1977) and the rat brain (Magil et al. 1981). Second, phospholipids could act as a cofactor by enhancing the absorption of DHA and EPA from the gut. Dietary supplementation of phospholipids that did not contain any DHA increased the concentration of DHA in plasma of rats fed a DHA-containing diet (van Wijk et al. 2011). The effects of phospholipid supplementation on the availability of DHA levels might be explained by an improved absorption of DHA from the gut, since dietary phospholipids are known to facilitate the emulsification of dietary fat in the lumen (Jones et al. 1992). Moreover, dietary phospholipids may increase the intestinal uptake of fat by increasing the formation of chylomicrons in enterocytes and subsequent secretion into the lymph (Nishimukai and Hara 2007, O'Doherty et al. 1973) (Fig. 2, left panel).

Together, these data show that the availability of membrane precursors is affected by their nutritional intake as well as by the intake of cofactors that influence precursor uptake and metabolism. Consequently, addition of nutritional cofactors potentially facilitates the synthesis of membrane phospholipids by enhancing the availability of the rate-limiting precursors.

**Modulation of neuronal membrane structure and function by specific nutritional compounds**

Biochemical and biophysical properties of the neuronal membrane are important determinants of normal functioning of membrane-dependent processes contributing to neuronal functioning. Fig. 4 displays a schematic representation of these membrane properties, including fatty acid and phospholipid composition, cholesterol level, sphingolipid level, lateral and rotational fluidity, membrane asymmetry, membrane thickness, and composition of distinct lateral membrane domains called lipid rafts. Membrane fluidity generally refers to the viscosity and stiffness of the membrane bilayer which is highly dependent on the fatty acid composition of the phospholipids. Lipid rafts are membrane microdomains with high levels of cholesterol, sphingolipids, and saturated fatty acids and a reduced level of PUFAs. Alteration of such biochemical and biophysical properties can markedly affect a multitude of membrane-dependent processes, including structure, function, and activity of receptors, ion channel activation, axonal neurotransmission, activity of membrane-bound enzymes, cell signaling, optimal exchange of nutrients and other molecules, and mitochondrial membrane function (Andersen and
Membrane lipids serve as sources of several intermediates of signal transduction pathways, including those associated with cell growth, differentiation, oxidative stress, inflammation, and apoptosis (Eyster 2007, Farooqui 2012). Neuronal membrane structure and function are subject to alterations induced by nutritional compounds. Dietary supplementation with omega-3 PUFAs has repeatedly been shown to affect cell membrane composition, thereby influencing its biophysical properties. Supplementation of cell culture media with DHA significantly increased membrane omega-3 PUFA levels in Aβ precursor protein (AβPP)-transfected Chinese hamster ovary (CHO) cells (de Wilde et al. 2010). Membrane omega-3 PUFA levels were also increased in brains of rats following oral supplementation with DHA (Hashimoto et al. 2006, Shahdat et al. 2004), dietary supplementation with DHA-containing phospholipids (Favreliere et al. 2003) or a multi-nutrient intervention including omega-3 PUFAs (de Wilde et al. 2003). In line with these results, dietary supplementation of FC to rats and...
mice has been shown to increase membrane omega-3 PUFAs levels in the brain (Broersen et al. 2013, de Wilde et al. 2011b). A high level of omega-3 PUFAs in neuronal membranes is associated with increased membrane fluidity and changed composition of lipid rafts, with favorable effects on numerous membrane-dependent processes (Mielke and Lyketsos 2006, Yehuda et al. 2002), including those that play a role in Aβ-related pathology.

Neuronal membranes are susceptible to the damaging effects of oxidative stress. Oxidative stress can cause lipid peroxidation and alter membrane composition, two processes particularly evident in AD (Axelsen et al. 2011). Extensive lipid peroxidation in biological membranes causes loss of fluidity, reductions in membrane potential, increased ionic permeability, and eventually cell death (Gutteridge 1995). Vitamin C (ascorbic acid), vitamin E (α-tocopherol) and selenium (as part of the enzyme glutathione peroxidase) serve as antioxidants to protect both the lipid precursors (i.e., DHA and EPA) and the resulting membrane components from lipid peroxidation (Gutteridge 1995). In addition, these nutrients are known to affect neuronal membranes: vitamin C contributes to optimal collagen synthesis (Switzer and Summer 1972), required for neurite outgrowth and synapse formation (Fox et al. 2007); selenium is part of selenoprotein P, which is required for normal synaptic functioning (Peters et al. 2006); and vitamin E is a structural component of neuronal membranes (Lucy 1972), primarily associated with PC molecules (Quinn 2004) and concentrated at neurite junctions (Monroe et al. 2005).

These observations imply that specific nutrients (e.g., omega-3 PUFAs, vitamin C, vitamin E, and selenium) can improve the structure and function of neuronal membrane and therefore may improve membrane-dependent processes.

In summary, stimulating the formation and function of neuronal membranes requires a combined increased supply of membrane precursors and cofactors. Availability of membrane precursors is affected by their nutritional intake as well as by the intake of cofactors that increase precursor availability. Besides increasing the availability of phospholipid precursors, cofactors may directly affect the neuronal membrane or membrane synthesis.
Combined administration of membrane precursors and cofactors modulates synapse formation, neurotransmission, and Aβ-related pathology

Increasing the availability of membrane precursors and cofactors hypothetically improves processes relevant in AD that are partly or largely dependent on membrane formation and function: synapse formation, neurotransmission, Aβ-related pathology, and ultimately cognitive performance. The data summarized below indicate that these processes are affected by combined administration of membrane precursors and cofactors. Fig. 5 represents a schematic overview of the putative mechanisms of action of the specific combination of nutrients present in FC.

Stimulating synapse formation

Synaptic communication takes place at the junctions between a terminal button of a pre-synaptic neuron and specific membrane structures of a post-synaptic neuron, e.g., dendritic spines. Synapses consist principally of neuronal membranes that are composed of phospholipids and which are associated with specific pre- and post-synaptic proteins. Synapse formation and elimination occurs throughout life (Trachtenberg et al. 2002) and individual brain synapses are presently understood to be continuously remodeled in the adult brain (Lardi-Studler and Fritschy 2007). Theoretically, the formation of new synapses requires the synthesis of new synaptic membrane and specific synaptic proteins. As summarized below, in vitro and in vivo studies have demonstrated that combined oral supplementation of the phospholipid precursors DHA or EPA, uridine or UMP, and choline not only increases the synthesis of phospholipids, but also increases neurite outgrowth, levels of specific pre- or post-synaptic proteins, and the number of dendritic spines, all indicative for new synapse formation. Several previously published reviews on this subject provide extensive summaries (Cansev et al. 2008b, Wurtman et al. 2010, Wurtman et al. 2009).
Increasing the availability of the nutritional precursors and cofactors, provided by Fortasyn Connect, stimulates membrane formation and function. In this way, this specific nutrient combination improves membrane-dependent processes that are of potential relevance for patients with AD. The membrane precursors and cofactors act in concert to increase the synthesis of membrane phospholipids via the Kennedy pathway and to increase neurite outgrowth, levels of specific pre- or post-synaptic proteins, and the number of dendritic spines, all prerequisites for new synapse formation (left panel). Neurotransmission is also increased by co-administration of membrane precursors and cofactors, not only via increased neurotransmitter levels and release, but
Targeting synaptic dysfunction with a specific nutrient combination

also via increased receptor signaling, e.g., by an enhanced G protein-coupled receptor activation (middle panel). By improving neuronal membrane structure and function, membrane precursors and cofactors reduce both Aβ production and toxicity resulting in decreased plaque formation and reduced neurodegeneration. These changes ultimately may lead to an improved learning and memory performance.

In nerve growth factor-stimulated PC-12 cells, uridine supplementation increases neurite outgrowth and neurite branching in a dose-dependent manner, possibly via increased PC synthesis (Pooler et al. 2005). In the same cell line, choline plus cytidine supplementation significantly increased neurite outgrowth (C.S. Wang and Lee 2000). DHA supplementation increased neurite outgrowth and neurite branching in embryonic hippocampal cultures from rats (Calderon and Kim 2004) and mice (Cao et al. 2009), and in neuronal cultures derived from mouse embryonic stem cells (He et al. 2009). A combination of omega-3 PUFAs and multiple vitamins and minerals was more effective in promoting neurite outgrowth in neuroblastoma cells (measured as average neurite length and the number of neurites per cell) compared with either omega-3 PUFAs or vitamins plus minerals alone (Shrivastava et al. 2005). Enrichment of cell culture medium with a combination of vitamins B₁, B₆, and B₁₂ increased neurite outgrowth from dorsal root ganglia (Fujii et al. 1996). The levels of neurofilament-70 and neurofilament-M proteins, two markers of neurite outgrowth, were increased after supplementation of uridine in PC-12 cells (Pooler et al. 2005), and after oral supplementation of UMP (L. Wang et al. 2005) or DHA plus UMP (Wurtman et al. 2006) in rodents. In addition, He et al. (2009) demonstrated that transgenic fat-1 mice (i.e., with intrinsic high levels of brain DHA) show significantly enhanced hippocampal neurogenesis, illustrated by an increased number of proliferating hippocampal neurons.

Supplementation of (combinations of) phospholipid precursors also increases the levels of proteins that are associated with pre- and post-synaptic membranes. In a study by Cao et al. (2009), DHA supplementation increased expression of the pre-synaptic vesicular protein synapsin-1 in mouse embryonic hippocampal cultures, whereas omega-3 PUFA deprivation caused a decrease in synapsin-1 expression in hippocampi of young mice. The loss of the post-synaptic proteins drebrin (actin-regulating dendritic spine protein) and post-synaptic density 95 (PSD-95), the increased cleavage of the cytoskeleton protein actin, and the resulting dendritic pathology induced in transgenic AD mice (Tg2576) when fed an omega-3 PUFA deficient diet, were prevented by dietary DHA enrichment (Calon et
al. 2004). DHA and/or UMP supplementation to gerbils and rats fed standard choline-containing diet increased levels of several synaptic proteins, including PSD-95, synapsin-1, and syntaxin-3 (Cansev et al. 2009, Cansev et al. 2008a, Cansev and Wurtman 2007, Sakamoto et al. 2007, Wurtman et al. 2006). The combined supplementation of DHA and UMP resulted in the largest effects on synaptic protein levels. These increases in pre- and post-synaptic protein levels indicate that the administration of phospholipid precursors in particular raises levels of membranes associated with synapses.

New synapses can form when a dendritic spine interacts with a pre-synaptic terminal button (Toni et al. 2007). Since dendritic spine growth precedes synapse formation, and new synapses form preferentially onto existing buttons (Knott et al. 2006), the rate of synaptogenesis depends in part on the numbers of dendritic spines that are being formed. He et al. (2009) demonstrated that high levels of brain DHA in transgenic fat-1 mice increased the hippocampal expression of synaptic proteins (e.g., PSD-95 and synapsin-1) and increased dendritic spines density of hippocampal pyramidal neurons. The effects of oral supplementation of DHA and/or UMP on dendritic spine number (in CA1 pyramidal hippocampal neurons) were examined in adult gerbils receiving standard choline-containing diets (Sakamoto et al. 2007). DHA supplementation (without UMP) caused dose-related increases in spine density (by 19% of control levels) in parallel with increases in membrane phospholipids and in specific pre- and post-synaptic proteins. This effect was almost doubled (up to 36% of control levels) if animals also received UMP. In contrast to these findings, oral supplementation with the omega-6 PUFA arachidonic acid had no effect on spine density in the adult gerbil hippocampus, indicating specificity of omega-3 PUFAs (Sakamoto et al. 2007). Similar studies were performed in pregnant rats and their offspring (Cansev et al. 2009). Brains of weanlings exhibited significant increases in hippocampal dendritic spine density; the largest effect was observed with the combined supplementation of DHA and UMP.

These observations suggest that DHA (and EPA), uridine, and choline act together to increase the synthesis of synaptic membranes and, consequently, synaptogenesis. Such an effect would be beneficial in situations with increased synapse loss leading to functional decline, like in AD.
Enhancing neurotransmission

Neurotransmission is a process in which neurotransmitters are released from the presynaptic terminal button into the synaptic cleft and have an excitatory or inhibitory effect on receptors of the post-synaptic membrane of, for example, a dendritic spine. Improving synaptic functioning or increasing the formation of synapses is expected to enhance synaptic neurotransmission. As described in detail below, several experiments have shown that membrane precursors and cofactors affect neurotransmitter levels and release, as well as receptor levels and functioning.

In experiments by Aid et al. (2005, 2003), dietary enrichment with omega-3 PUFAs (including DHA) or DHA-containing phospholipids normalized omega-3 PUFA deficiency-induced changes in hippocampal basal and stimulated acetylcholine (ACh) release; this was ascribed to changes observed in membrane composition. Furthermore, dietary DHA-containing phospholipids have been demonstrated to restore aging-induced reductions in hippocampal basal and stimulated ACh release (Favreliere et al. 2003). L. Wang et al. (2007) showed that the consumption of a diet containing UMP and standard levels of choline by young and aged rats led to increased striatal ACh levels and increased basal and stimulated release of ACh, which was paralleled by an increase in striatal PC, PE, and PS levels. Striatal dopamine levels and stimulated release of dopamine were found to be increased in aged rats following consumption of UMP (L. Wang et al. 2005). The increase in neurotransmitter content and release might be ascribed to a UMP-induced increase in neuronal membrane formation, and hence synapse formation and/or increased synaptic vesicle formation. In addition, by increasing PC, UMP might indirectly increase choline availability for the synthesis of ACh, since choline can be made available from PC in neuronal membranes (Ulus et al. 1989). Rats fed choline enriched diets also show increased brain ACh levels (Cohen and Wurtman 1976) and increased cortical release of ACh (Beninger et al. 1984), in which choline probably acts as a direct precursor for ACh synthesis in the brain. In an experiment by Cansev et al. (2008a), oral supplementation with UMP, DHA, or the combination of UMP and DHA, partially restored dopaminergic neurotransmission in rats with unilateral 6-hydroxydopamine striatal lesions. Striatal dopamine content in both the intact and lesioned striatum was increased, and the combination of UMP plus DHA was more effective than supplementation of either nutrient alone. UMP and DHA were hypothesized to ameliorate the impairment in dopaminergic transmission by increasing the amount of synaptic membrane, as increased brain phospholipid levels and synaptic protein levels were also observed in these animals.
Administration of nutrients that improve membrane structure and function can also influence receptor signaling. The combination of DHA, EPA, uridine, choline, folate, vitamin B_{12}, vitamin B_{6}, phospholipids, vitamin C, vitamin E, and selenium (i.e., FC) has been demonstrated to synergistically enhance muscarinic M1 G protein-coupled receptor activation in vitro (Savelkoul et al. 2012). Muscarinic receptor activation is relevant for AD as both muscarinic and nicotinic ACh receptor abnormalities are known to be involved in the pathology of AD (Kihara and Shimohama 2004). Addition of single nutrients to the cell culture medium had little effect on muscarinic M1 receptor response. Combining DHA, uridine, and choline resulted in an increased receptor response and the subsequent additions of B-vitamins, antioxidants, and PUFAs further increased the response. The largest receptor response was observed with the full combination of membrane precursors and cofactors contained within FC, indicating a concerted action of these nutrients on membrane-dependent processes (Savelkoul et al. 2012). In vivo studies have also demonstrated effects of dietary intake of specific nutrients, or combinations thereof, on receptor levels and/or binding. Dietary omega-3 PUFA deficiency has previously been shown to decrease muscarinic receptor binding in rat hippocampi (Aid et al. 2003), to decrease levels of the α-amino-3-hydroxy-5-methylisoxazole (AMPA) receptor subunit GluR-1 and the N-methyl-D-aspartate (NMDA) receptor subunits, NR1, NR2a, and NR2b, in hippocampi of young mice (Cao et al. 2009), and to decrease levels of NR2a and NR2b in the cortices and hippocampi of aged transgenic mice (Tg2576) (Calon et al. 2005). The latter effect was reversed by dietary DHA enrichment (Calon et al. 2005). Feeding rats a diet enriched with a combination of omega-3 PUFAs, B-vitamins and antioxidants enhanced hippocampal muscarinic M1 receptor binding, whereas a diet additionally enriched with choline, phospholipids, and other nutrients increased binding to both muscarinic M1 and serotonergic 1A receptors (Farkas et al. 2002). Sakamoto et al. (2007) demonstrated significantly elevated expression of GluR-1 in gerbil hippocampi after treatment with DHA alone, and to a greater extent with combined oral supplementation of DHA and UMP.

Reducing Aβ production and toxicity
Soluble Aβ oligomers have been proposed as the neurotoxic pathogenic agents inducing the loss of dendritic spines and synapses in AD (Bittner et al. 2012, Haass and Selkoe 2007, Koffie et al. 2011, Selkoe 2002, Shankar et al. 2007, Shankar et al. 2008). It has been suggested that the neurotoxic cascade of Aβ leading to synapse loss and synaptic dysfunction may be initiated at neuronal cell membranes and that soluble Aβ oligomers
disturb neuronal membrane properties by binding to membrane components (Eckert et al. 2010, Williamson and Sutherland 2011). The composition of neuronal membranes may in turn influence the membrane-disrupting properties of Aβ and therefore its toxicity (Florent-Bechard et al. 2009). Moreover, membrane structure and function have been documented to exert a direct impact on AβPP processing and the production of Aβ (Hartmann et al. 2007, Williamson and Sutherland 2011). This is comprehensible as all AβPP processing enzymes as well as AβPP itself are integral membrane proteins. For example, β- and γ-secretase activity is influenced by the composition of lipid rafts in which these enzymes are concentrated (Grimm et al. 2011b, Wolozin 2001) and membrane bilayer thickness has been shown to directly affect the activity and cleavage specificity of γ-secretase (Winkler et al. 2012). Thus, it can be hypothesized that specific nutritional compounds which improve neuronal membrane composition, structure, and function reduce both Aβ toxicity and Aβ production.

Supplementation with nutritional membrane precursors and cofactors has been demonstrated to be effective in reducing Aβ production and toxicity in several in vitro models. Grimm et al. (2011b) investigated the effect of increasing the neuronal membrane DHA content on amyloidogenic and non-amyloidogenic AβPP processing in AβPP-transfected and non-transfected neuroblastoma cell lines and purified membranes from mouse brain. They demonstrated that supplementation of DHA directs the processing of AβPP toward the non-amyloidogenic pathway, effectively reducing Aβ production by directly decreasing the activity of β- and γ-secretase and increasing the protein stability of α-secretase. In line with these findings, incubation of AβPP-transfected neuroblastoma cells (Sahlin et al. 2007) or AβPP-transfected CHO cells (de Wilde et al. 2010) with DHA effectively reduced Aβ levels. In an experiment by Oksman et al. (2006), DHA supplementation of a neuroblastoma cell culture was shown to reduce Aβ production in a dose-dependent manner. DHA or EPA incubation protected rat embryonic cortical neurons and neuroblastoma cells from the toxic effects of soluble Aβ oligomers (Florent et al. 2006). It was suggested that DHA enrichment had induced changes in neuronal membrane properties, thereby increasing protection against Aβ toxicity. In Cos-7 SP-C99-transfected cells (expressing the C-terminal fragment of AβPP, AβPP-C99) supplemented with different phospholipids, modulation of Aβ production was depended on the composition of phospholipids in the membrane bilayer, influencing intra-membranous proteolysis of AβPP (Amtul et al. 2010). A combination of choline plus cytidine significantly reduced
amyloidogenic processing of AβPP in PC-12 cells, possibly by the concurrently observed effects on membrane PC levels (C.S. Wang and Lee 2000).

The potential protective effects of nutritional components have also been investigated in transgenic mouse models of AD (AβPP/PS1; Tg2576; 3xTg-AD; TgCRND8). Deficiency of folate, vitamin B$_{12}$, and vitamin B$_{6}$ has been associated with significant increases in Aβ deposition (Fuso et al. 2008, Zhuo and Pratico 2010), whereas transgenic mice supplemented with vitamin E showed reduced levels of Aβ (Conte et al. 2004, Sung et al. 2004). Dietary supplementation with omega-3 PUFAs in transgenic mouse models of AD reduced Aβ levels (Green et al. 2007, G.P. Lim et al. 2005, Oksman et al. 2006), reduced plaque load (Hooijmans et al. 2009, G.P. Lim et al. 2005), lowered vascular Aβ deposition (Hooijmans et al. 2007, Hooijmans et al. 2009), altered AβPP processing (G.P. Lim et al. 2005), and reduced levels of presenilin 1 (PS1, part of the γ-secretase complex) (Green et al. 2007). In vivo β- and γ-secretase activities have also been shown to be significantly decreased in normal C57Bl/6J mice fed an omega-3 PUFA enriched diet compared with mice fed a control diet (Grimm et al. 2011b). Although the effects of omega-3 PUFAs (including DHA) on Aβ production and levels in vivo seem robust, several studies do not show consistent effects on every parameter measured. For instance, Oksman et al. (2006) found effects on soluble and insoluble Aβ levels, but no effects on Aβ plaque load. Moreover, in other studies using transgenic mouse models of AD, no effects of dietary omega-3 PUFAs on Aβ levels were observed (Arendash et al. 2007, Arsenault et al. 2011). The inconsistent results might be due to differences in study design, although other studies suggest that the effectiveness of nutritional supplementation on Aβ pathology depends on the combined availability of specific nutrients. AβPP/PS1 transgenic mice fed an FC-enriched diet had decreased total brain Aβ$_{42}$ levels, Aβ$_{40}$ levels, and reduced amyloid plaque burden in the hippocampus (Broersen et al. 2013). These mice showed reduced plaque-associated neurodegeneration in the brain, indicating that dietary enrichment with this combination reduces AD-like pathology. In contrast, in the same study, these protective effects were not observed in mice fed a diet enriched in DHA or DHA plus UMP, showing that other nutrients in FC contributed significantly to the overall effect of this diet. Furthermore, supplementation with this nutrient combination protected cholinergic neurons from Aβ-induced toxicity, as evidenced by preserved immunoreactivity for the membrane-bound enzymes choline acetyltransferase (ChAT) and vesicular ACh transporter (VACHT) following ICV infusion of Aβ in rats (de Wilde et al. 2011b). It was speculated that the protective effects of the diet are mediated by the
improved integrity of the neuronal membranes, thereby limiting the membrane binding and membrane-disrupting properties of Aβ (de Wilde et al. 2011b).

Thus, improving neuronal membrane structure and function by co-administering membrane precursors and cofactors potentially reduces both Aβ production (by reducing amyloidogenic AβPP processing) and Aβ toxicity (by limiting the membrane-disrupting properties of Aβ) resulting in decreased plaque formation and reduced neurodegeneration. Hypothetically, this in turn diminishes the neurotoxic cascade of Aβ that leads to synapse loss and synaptic dysfunction.

Membrane precursors and cofactors improve memory and cognition in rodent models

Since supplementation with membrane precursors and cofactors can stimulate synapse formation, enhance neurotransmission, and decrease Aβ-related pathology, it was hypothesized that these nutrients would have significant effects on memory and other cognitive processes. Studies in various animal species and models support this hypothesis.

An improvement in behavior with dietary supplementation of omega-3 PUFAs, DHA, or EPA has been observed in healthy rodents (Gamoh et al. 1999) and models of cognitive dysfunction, including those specific for AD (Arsenault et al. 2011, Calon et al. 2004, Hashimoto et al. 2002, Hashimoto et al. 2009, Hashimoto et al. 2005, Hooijmans et al. 2009, Oksman et al. 2006, Petursdottir et al. 2008), although this is not consistently observed (Arendash et al. 2007). These effects can be augmented by co-administration of specific nutrients as pointed out in several experiment. Dietary UMP supplementation ameliorated memory deficits associated with rearing rats under impoverished conditions (Teather and Wurtman 2006). Using the same model, Holguin et al. (2008a) found that the combination of UMP and DHA was more effective at reducing the memory deficits in these rats as compared to supplementation of UMP or DHA alone. This effect may be mediated through the concurrently observed enhancement of synaptic membrane synthesis, as the authors suggested. In addition, oral UMP and/or DHA supplementation was also shown, in normal gerbils, to enhance learning and memory, with concomitant increased brain phospholipid levels. The largest effects on learning and memory again occurred when DHA and UMP were supplemented in combination (Holguin et al. 2008b).

Intake of DHA, PC, or their combination also enhanced learning ability and brain function
in aged mice (S.Y. Lim and Suzuki 2000). Spontaneously hypertensive rats exhibit deficiencies in selective attention and spatial learning, which were improved following dietary supplementation with UMP and choline (de Bruin et al. 2003). In a rat model of chronic cerebral hypo-perfusion, a diet enriched with omega-3 PUFAs, choline, B-vitamins, phospholipids, and antioxidants restored hypo-perfusion-induced spatial learning and memory impairment (de Wilde et al. 2002). The same nutritional combination also improved spatial learning and memory in normal rats (de Wilde et al. 2003). Moreover, in both experiments, a diet with fewer additives (e.g., lacking supplemented choline and phospholipids) was less effective (de Wilde et al. 2002, de Wilde et al. 2003), suggesting that supplementation with the indicated combination of nutrients was necessary to induce the largest effects on performance. In rats pre-infused with Aβ, dietary enrichment with FC prevented the Aβ-induced reduction in exploratory activity (de Wilde et al. 2011b). Supplementation of this nutrient combination to the diet of aged AβPP/PS1 transgenic mice improved spatial learning and memory (Wiesmann et al. 2013). Dietary enrichment with FC also normalized reduced exploration of odor of conspecifics and impaired spatial learning in AβPP/PS1 transgenic mice (Broersen et al. 2011). In this study, FC was more effective than omega-3 PUFA alone, indicating that the effects of DHA on cognition in AβPP/PS1 mice can be further supported by the addition of other membrane precursors and cofactors.

Taken together, the effects of membrane precursors and cofactors on improving cognitive performance have been shown in various animal models. Although administration of single nutrients may already be effective, combined intake of these nutrients is required in order to reach a higher efficacy. Administration of membrane precursors and cofactors can increase cognitive performance probably by their effects on synapse function and formation, neurotransmission, and in AD-specific models also by reducing Aβ-related pathology. More preclinical studies on the effects of FC on memory and cognition are currently ongoing within the framework of the LipiDiDiet project.

Clinical utility of the specific nutrient combination in AD

The experimental studies on FC in the previous sections indicate that this nutrient combination has potential clinical utility in AD. A nutritional product intended to manage a specific disease like AD via dietary intervention is commonly referred to as a medical food. A medical food is a food formulated for enteral intake by patients, taken under physician
supervision, and intended to meet the specific nutritional requirements identified for a disease or condition, which cannot be met by modification of the normal diet. Several factors proposed to contribute to a disease-specific nutritional requirement in AD, including: 1) alterations in nutrient intake, 2) compromised nutrient absorption from the gut and uptake into the brain and reduced endogenous biosynthesis of nutritional compounds, and 3) an increased utilization of specific nutrients for neuronal membrane and synapse formation to compensate for the increased loss of synapses (Mi et al. 2013). The diet of AD patients is not expected to provide the levels to meet these nutritional requirements. In fact, a recent systematic review and meta-analysis indicated that, in comparison with age-matched cognitively intact individuals, AD patients have lower plasma levels of several nutrients, including vitamins C, vitamin E, folate, vitamin B₁₂, and omega-3 PUFAs (Lopes da Silva et al. 2014). Thus, while AD patients may have disease-specific nutritional requirements that are associated with pathological processes, many have lower circulating levels of these nutrients. To address these putative disease-specific nutritional requirements, the medical food Souvenaid, containing Fortasyn Connect, was designed to target synaptic dysfunction in early AD.

In early AD, memory dysfunction is a key manifestation and is associated with increased loss of synapses (Selkoe 2002, Sperling et al. 2011, Terry et al. 1991). Reducing synapse loss and improving synaptic function may preserve or improve neuronal communication and thereby positively affect memory and other cognitive functions. A clinical study program that covers a broad part of the AD spectrum is investigating the effects of the aforementioned medical food on memory and cognitive performance and the underlying hypothesis of ameliorated synaptic loss and dysfunction. In an initial randomized, double-blind, controlled proof of concept study of 225 drug-naïve patients with mild AD (Souvenir I), the medical food (125 mL/4 fl oz) taken once daily for 12 weeks significantly improved memory using the Wechsler Memory Scale–revised delayed verbal recall task as the primary outcome measure (Fig. 6, panel A) (Scheltens et al. 2010). In patients with a more advanced stage of AD receiving standard AD medication, no effect of the intervention on cognition was observed (S-Connect study) (Shah et al. 2011), which suggest that this medical food offers the greatest potential when applied to earlier stages of AD. The Souvenir II study recently confirmed the efficacy of the medical food on memory in drug-naïve patients with mild AD, and also extended the result through a longer intervention period of 24 weeks and through utilization of the whole memory domain z-score of a Neuropsychological Test Battery as the primary endpoint (Fig. 6, panel B) (Scheltens et al.
EEG measures in this study served as secondary outcomes to investigate the biological effect on synaptic function. The EEG signal reflects synchronous activity of many synapses and is therefore a derivative of underlying synaptic function and neuronal communication. Quantitative EEG analyses and more advanced functional network analyses suggest that the intervention preserves functional brain connectivity (Scheltens et al. 2012) and the functional brain network organization (de Waal et al. 2014) in patients with mild AD, counteracting the pattern usually seen in AD. These findings support the hypothesis that this medical food stimulates synapse formation and function in early AD.

The clinical studies to date provide evidence that Souvenaid is well tolerated and has a positive safety profile, including use in combination with current drug therapy for AD. In three large clinical trials, no differences were found in tolerance and safety measures between patients on the active product compared to patients on the control product (Scheltens et al. 2010, Scheltens et al. 2012, Shah et al. 2011). This medical food has a beneficial effect on memory function in early AD and support the hypothesis that improving synaptic functioning in early AD may be related to improved memory performance. Since synaptic dysfunction already occurs in the early stages of AD, targeting synaptic loss and membrane-related pathology with this intervention might be most efficacious when applied to earlier stages of AD, when damaging patho-physiological changes have not yet accumulated to an irreversible degree. Additional studies are ongoing to investigate the longer-term outcome of this intervention in early and prodromal AD to broaden the understanding of its clinical utility. These studies also include imaging and biomarker techniques in order to further investigate the mode of action of the specific nutrient combination Fortasyn Connect on synaptic dysfunction.
Targeting synaptic dysfunction with a specific nutrient combination

Fig. 6  Primary endpoints of two human intervention studies with the medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect. The effects of the medical food (Active) were compared with a control product (Control) that was isocaloric and similar in flavor and appearance to the active product but lacked the specific nutrient combination. Compared with the control product, the active product significantly improved memory performance in drug-naïve patients with mild AD in both studies. Souvenir I study (A): percentage of patients showing decline, no change or improvement on the Wechsler Memory Scale–revised delayed verbal recall score after 12 weeks of supplementation with active or control product (Scheltens et al. 2010). Souvenir II study (B): change from baseline in the Neuropsychological Test Battery memory composite score during 24 weeks of supplementation with active or control product, with a significant difference in trajectories over time between the groups (p = 0.023) (Scheltens et al. 2012). Error bars represent standard errors. Figures are reprinted from Scheltens et al. (2010) (A) and Scheltens et al. (2012) (B), with permission from Elsevier and IOS Press, respectively.
Disclosure statement
Authors’ disclosures available online:

Acknowledgements
Figures 1, 2, 4, and 5 were designed in collaboration with Medical Visuals, Maartje Kunen.
All authors are employees of Nutricia Advanced Medical Nutrition, Nutricia Research,
Utrecht, The Netherlands.

List of abbreviations
ACh, acetylcholine
AD, Alzheimer’s disease
AMPA, α-amino-3-hydroxy-5-methylisoxazole
ANOVA, analysis of variance
Aβ, amyloid-β
AβPP, Aβ precursor protein
BHMT, betaine–homocysteine methyltransferase
CDP, cytidine diphosphatase
ChAT, choline acetyltransferase
CHO, Chinese hamster ovary
CTP, cytidine triphosphate
DAG, diacylglycerol
DHA, docosahexaenoic acid (22:6n-3)
EEG, electroencephalography
EPA, eicosapentaenoic acid (20:5n-3)
FC, Fortasyn Connect
FDG-PET, 18F-fluorodeoxyglucose positron emission tomography
fMRI, functional magnetic resonance imaging
ICV, intracerebroventricular
MCI, mild cognitive impairment
NMDA, N-methyl-D-aspartate
PC, phosphatidylcholine
PC-12, pheochromocytoma cells
PE, phosphatidylethanolamine
PEMT, phosphatidylethanolamine-\(N\)-methyltransferase
PI, phosphatidylinositol
PS, phosphatidylserine
PS1 or PS2, presenilin
PSD-95, post-synaptic density 95
PUFA(s), polyunsaturated fatty acid(s)
SM, sphingomyelin
UMP, uridine monophosphate
UTP, uridine triphosphate
VACHT, vesicular acetylcholine transporter
References


Targeting synaptic dysfunction with a specific nutrient combination


de Wilde MC, van der Beek EM, Kiliaan AJ, Leenders I, Kuipers AA, Kamphuis PJ, and Broersen LM. Docosahexaenoic acid reduces amyloid-beta(1-42) secretion in human AbetaPP-transfected...


Chapter 2


Targeting synaptic dysfunction with a specific nutrient combination


Chapter 2


Targeting synaptic dysfunction with a specific nutrient combination